evotec
German pharmaceutical company Evotec reported a "challenging" first quarter as it revealed a loss from the same period last year. Group revenues decreased by 2%, excluding currency effects, to €208.7 million ($226.6 million) from €213.6 million last year. Adjusted EBITDA totalled €7.8 million, compared to €34 million previously. The Hamburg-based firm, which specializes in drug discovery and development, expects group revenue to grow by "a double digit percentage" for the year, after coming in at €781.4 million in 2023. Laetitia Rouxel, chief financial officer, said on Wednesday that despite t...
DPA International
German pharmaceutical company Evotec reported a "challenging" first quarter as it revealed a loss from the same period last year. Group revenues decreased by 2%, excluding currency effects, to €208.7 million ($226.6 million) from €213.6 million last year. Adjusted EBITDA totalled €7.8 million, compared to €34 million previously. The Hamburg-based firm, which specializes in drug discovery and development, expects group revenue to grow by "a double digit percentage" for the year, after coming in at €781.4 million in 2023. Laetitia Rouxel, chief financial officer, said on Wednesday that despite t...
DPA Breaking News
German pharmaceutical company Evotec reported a "challenging" first quarter as it revealed a loss from the same period last year. Group revenues decreased by 2%, excluding currency effects, to €208.7 million ($226.6 million) from €213.6 million last year. Adjusted EBITDA totalled €7.8 million, compared to €34 million previously. The Hamburg-based firm, which specializes in drug discovery and development, expects group revenue to grow by "a double digit percentage" for the year, after coming in at €781.4 million in 2023. Laetitia Rouxel, chief financial officer, said on Wednesday that despite t...
DPA
New collaborations at the German drug maker Evotec are in part behind Wednesday's report of a rise in full-year revenue, the company said. The group has announced a priority reset, which is expected to result in an annualized Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) improvement of over €40 million ($42.8 million), the company said in a statement. Mario Polywka, chief executive of Evotec, said: "Evotec's business displayed great resilience in a challenging market environment. Our central focus for 2024 is to protect our strong balance sheet and refocus the company...
DPA International
New collaborations at the German drug maker Evotec are in part behind Wednesday's report of a rise in full-year revenue, the company said. The group has announced a priority reset, which is expected to result in an annualized Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) improvement of over €40 million ($42.8 million), the company said in a statement. Mario Polywka, chief executive of Evotec, said: "Evotec's business displayed great resilience in a challenging market environment. Our central focus for 2024 is to protect our strong balance sheet and refocus the company...
DPA Breaking News
New collaborations at the German drug maker Evotec are in part behind Wednesday's report of a rise in full-year revenue, the company said. The group has announced a priority reset, which is expected to result in an annualized Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) improvement of over €40 million ($42.8 million), the company said in a statement. Mario Polywka, chief executive of Evotec, said: "Evotec's business displayed great resilience in a challenging market environment. Our central focus for 2024 is to protect our strong balance sheet and refocus the company...
DPA
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら